The U.S. says it will defend India’s Kovacsin Covid Delta variants

The results of the second phase of the experiment are currently out

Washington: The United States and the National Institutes of Health (NIH) have said that Kovacin Delta, a covid vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), will neutralize alpha variants.

The NIH found that covaxin had been shown to produce antibodies against B1.1.7 (alpha) and B1.617 (delta) variants in the blood of people who received it. These variants were first found in India and the UK.

“The covaxin contains the disabled form of the covid virus, which produces antibodies against the virus and enhances immunity,” the NIH said in a second-stage test. The NIH said it would release the results of the third phase of testing by the end of this year.

Interim results of the third phase trial also show that the vaccine is effective. It is 78 percent effective against symptomatic Kovid and 100 percent effective against severe Kovid, including hospital treatment. The NIH says it is 70 percent effective when asymptomatic.

Also Read: Everything you need to know about the fourth vaccine licensed in India – the modern vaccine